As the latest innovations are cropping up daily, the health sector is also enjoying those benefits. Several methods of testing and detecting various diseases are being developed day by day. For instance, identifying conditions like cancer at the early stages is growing as the day goes by, and recent discoveries show that any disease can now be detected at its most initial stage.

Detecting Cancer Through DNA Evaluation of Fragments for Early Interception Packaging

A novel test has been discovered recently which can detect different kinds of cancer from blood samples. Researchers have developed the new method at the Johns Hopkins Cancer Center, which relies on original DNA packaging. The technique does not rely on tumors for it to detect the presence of cancer cells.

The DNA evaluation of fragments for early interception (“DELFI”) method works by analyzing cell-free DNA (cfDNA) in a patient’s bloodstream. It also uses artificial intelligence in identifying the abnormal DNA structures floating in the blood. In normal cases, the DNA is always packaged in a healthy cell nucleus in a well-organized way. However, if a cell is diagnosed with cancer, the DNA packaging is still disorganized compared to a healthy cell. The disorganization leads to their release into the bloodstream in a very unsystematic way.

DELFI can detect abnormalities in the amount and size of the DNA based on its packaging. Due to these abnormalities, the test identifies the presence of cancer faster and in an easy way. The current analysis used in detecting cancer works by either detecting methylation or mutation. Methylation is a process involving chemical reactions in which methyl groups are added to the DNA, which rarely occurs.

Furthermore, the efficiency of DELFI has been tested by using blood samples from cancer and non-cancer patients. Its effectiveness in detecting cancer was found to be between 55%-99% depending on the type of cancer. The method was used to test lung, pancreatic, ovarian, gastric, breast, bile duct, and colorectal cancers. Besides, DELFI was also able to identify the tissues from which lung, chest, and colon cancers originated from.

According to one of the researchers, the potentiality of DNA Evaluation of Fragments for Early Interception in detecting cancer at its early stages is encouraging. The researchers are working closely with other relevant bodies to make this test available to cancer patients quickly. Biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) are likely to follow this research closely as it could have huge potential in the industry.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Each year, approximately 1.35 million people die as a result of road traffic accidents. On top of that conventional vehicles run on non-renewable fossil fuels, and the impact they have on the environment is massive. Still, roads remain a crucial aspect of most countries’ infrastructure, especially developing nations that don’t have a countrywide railway system. Governments are tackling the issue of carbon emissions and global warming by phasing out internal combustion engine vehicles for electric cars.

As electric vehicles (“EVs”) become more mainstream across the world, one question that has crossed the mind of anyone who considered making the switch to green energy is just how much safer are electric vehicles? Well, the honest answer is yes, electric vehicles tend to be safer than internal combustion engine vehicles. You see, electric vehicles are fundamentally different from traditional cars, and automakers design their EVs with the driver’s and pedestrians’ safety in mind.

For starters, EV battery packs are super heavy, weighing up to 551 pounds. The battery pack is usually placed on the floor of the vehicle, thus lowering its center of gravity. This makes them a lot more stable than traditional vehicles and makes them less likely to tumble or flip.

Electric vehicles also need less components to run, thus consuming less room and providing more crumple space in case of an accident. Crumple spaces or zones are areas of the vehicle that are designed to deform and crumple in a collision. This absorbs some of the energy of the impact and prevents it from being transmitted to the occupants.

With less components to install in the vehicle, EV makers have more room, allowing them to carefully plan and execute better frontal, side, and rear crumple spaces and provide more protection for occupants in case of an accident. Additionally, the onboard systems on an EV log the drivetrain activity and perform pre-diagnostics to prevent potential failures of any sub-system. Thus, the vehicles are better maintained and less likely to suffer any breakdowns or accidents.

Another risk with internal combustion engine (“ICE”) vehicles is catching fire in certain unusual circumstances. Electric vehicles run on lithium-ion battery packs rather than a tank of flammable petrol or diesel, and this reduces their risk of catching fire or exploding in case of an accident. Most EV manufacturers also use cell isolation and division of battery packs into arrays to reduce the potential damage in case of a malfunction. The battery packs are always under the watchful eye of a battery management system which continuously monitors their state and temperature, with a cooling mechanism keeping the battery temperature low while the vehicle is running.

Plenty of the features built into electric vehicles make them a lot safer than traditional vehicles. They are more stable on the road, constantly monitor systems to prevent issues before they become severe and are more likely to keep the occupants safe in case of an accident. It is therefore no wonder that leading payment solutions providers like Net Element (NASDAQ: NETE) are happy to be associated with the green car sector due to its inherent emphasis of safety in all aspects of EVs.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• Producing clean energy with zero carbon emissions, zero air pollution
• Recycled over 6 million pounds of uranium to produce clean, carbon-free energy
• Positioned to participate in the cleanup of Cold War-era uranium sites

The country’s largest producer of uranium and the leading producer of vanadium, Energy Fuels (NYSE American: UUUU) (TSX: EFR), is also one of the greenest companies in the United States. As the demand for clean energy grows, UUUU appears to be well positioned to benefit from the focus on being green.

As demand for clean energy increases, so does the need for nuclear energy. In 2019, 20% of all electricity and 55% of all clean-energy production in the United States was nuclear (http://ibn.fm/5Mv3t). Meanwhile, fossil fuels still account for a majority of greenhouse gas emissions. These finite resources continue to harm the environment even though there are better alternatives, chief among them, nuclear energy (http://ibn.fm/ICk09).

Nuclear energy is clean energy because it produces zero carbon emissions and zero air pollution. Power is generated through fission, a process that splits uranium atoms to produce energy. Heat, released by fission, turns water into steam, which spins a turbine and generates electricity. No harmful byproducts are emitted throughout this process. Since reactors only extract a small percent of the energy in their fuel, the uranium can be recycled.

An excellent clean-energy option that operates 24/7, nuclear is affordable and offers high-capacity factors and grid stability, while producing zero carbon emissions and zero air pollution. The energy source also has a small footprint in comparison to other renewable energy sources. For example, wind farms require 360 times more land area and solar photovoltaic plants require 75 times more space than the one square mile it takes to operate a typical 1,000-megawatt nuclear facility in the U.S. (http://ibn.fm/sNmMJ).

To date Energy Fuels has recycled over 6 million pounds of uranium from its alternate feed recycling program. The electricity that has been produced from this program has avoided 85 million tons of CO2 emissions that would have been created with coal.

Over the past 15 years, Energy Fuels has produced over one-third of all U.S. uranium, which is more than any other company except Cameco. While the United States is the largest consumer of uranium in the world, consuming 55 million pounds each year, it produces under 1% of its needs (http://ibn.fm/uDDHU), importing the rest from foreign countries, including Russia, Canada, Kazakhstan, Namibia, Australia, Uzbekistan, Niger, South Africa and others, and drawing down finite inventories (http://ibn.fm/wBiAV).

Energy Fuels is leading a charge to change this, while maintaining its commitment to operating green. Over the past few years, the company has led industry efforts to have the U.S. government recognize the importance of domestically produced uranium. These efforts have included the 2018–2019 Uranium Section 232 (http://ibn.fm/AAas5), the Nuclear Fuel Working Group (http://ibn.fm/EvJTO) and the U.S. strategic uranium reserve (http://ibn.fm/zVth0).

Energy Fuels is based out of Colorado and has three strategic uranium facilities. The White Mesa Mill in Utah is currently producing uranium from alternate feeds, and it is located near some of the largest and highest-grade uranium mines and projects in the country. The Nichols Ranch Plant is in Wyoming, operated until April 2020, and has significant future expansion potential, including 34 fully licensed well fields with significant in-ground uranium resources. The third facility is the Alta Mesa Plant located in Texas, a low-cost production site currently on standby with a total operating capacity of 1.5 million pounds of uranium per year.

As the only facility in the U.S. that can recycle material into usable uranium, Energy Fuel’s White Mesa Mill is also well positioned to participate in the cleanup of Cold War-era uranium sites. Right now, the U.S. has access to $1.7 billion for the cleaning up of abandoned uranium mines on and near the Navajo Nation. Plus, the company is quickly entering the rare earth element (“REE”) space.

Energy Fuel has more uranium production facilities, capacity and experience than any other uranium company in the country. By the end of 2020, UUUU plans to be debt free and working toward opportunities that further align with being one of the greenest companies in the country. As nuclear energy increases in demand, as additional oversight is placed on imports, and as the government pushes forward in its efforts to clean up abandoned mines, Energy Fuels is well positioned and ready for growth.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Technology has helped a lot of people to monitor their homes remotely. It has been amazing to use smart doorbells and thermostat applications. Could such techniques also be imported to the health sector? It is possible to cooperate with such technologies, such as Wi-Fi based devices, which may aid patients with breathing difficulties. There are multiple ways that Wi-Fi based devices can be used in delivering oxygen to patients.

The internet is the technology that allows several tools used daily to be connected to a computer, and innovators are aiming to link the hospital’s oxygen concentrators to an app. This will enable physicians to monitor all the concentrators in different wards easily. It will also allow them to act swiftly in case of any problem.

The application will consist of an oxygen sensor, ESP32 Wi-Fi microcontroller, a real-time clock, and a temperature sensor. These sensors will be gathering information such as oxygen concentration, hours the machine has been operating, and the temperature of the compressor. The data will then be relayed to the microcontroller converting it into a readable form of information sent to an application on a laptop through Wi-Fi.

The information will then be displayed on a simple dashboard on the laptop with different values in their specified areas. These values will be constantly updated on the panel after every eight seconds.

Acquiring this timely data on an operating oxygen machine will allow tracking its performance online without physically checking it. It will also save a lot of time, especially when dealing with several concentrators. Furthermore, the crucial information will also enhance accuracy on how long the oxygen concentrator has been functioning.

Additionally, the tracking will also help in determining when the machines should be serviced. The preventive measure will reduce cases of disruptive breakdowns, making it easier to ensure oxygen is available to patients when required.

The Wi-Fi connected device will help medics respond fast in case anything goes wrong. For instance, at the dashboard, a trigger can be set to alert personnel in case a value from a given feed reaches a certain level. The trigger can be in the form of an email that automatically sends an alert to the medics when the value has been reached.

Having this information will also be of help to the physicians in case the oxygen concentrator breaks down. Since there would be stored data, reviewing the history of oxygen concentration and component temperature will be useful in troubleshooting the mistake.

What is the next step?

Since the model is already built, the next procedure is to test and establish its balance and efficiency. It should be done in labs without being connected to patients. This test will enable the innovators to see the device’s challenges and how those challenges can be remedied.

If the innovation is a success, biomedical entities like Genprex Inc. (NASDAQ: GNPX) will certainly welcome it since it takes the task of saving life a whole lot easier.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The months after the coronavirus broke out were characterized by a severe decline in commerce. Industries like airlines, food service and tourism were especially hit, with a large chunk of the more than 30 million Americans who lost their jobs coming from these sectors. Cannabis, on the other hand has weathered the storm fairly well. There was a spike in marijuana sales in the weeks leading up to the shutdown and self-isolation orders and in the months since, several states have reported record breaking sales.

On Monday, Illinois’ Department of Financial and Professional Regulation announced that the state had recorded another record-breaking month of recreational marijuana sales. Illinois is reporting nearly $61 million in adult-use cannabis sales for the month of July, with dispensaries selling 1,270.063 marijuana items, a new record. Illinois residents bought $44,749,787 worth of marijuana products while out of state visitors accounted for $16,207,193 worth of marijuana. Sales to out of state customers support Gov. J.B. Pritzker’s prediction during his State of the State address in January that cannabis tourism would boost the state’s tax revenue.

Marijuana sales in July trampled on the record previously set in June. Illinois reported more than $47.6 million in total sales that month with stores selling nearly a million (994,545) marijuana products. In-state residents accounted for $35.3 million while out of state visitors bought $12.4 million worth of marijuana products. At a time when states are seeing a massive reduction in taxes and their coffers are bleeding money, tax revenue from cannabis sales are a godsend.

Since retail cannabis sales started in January, the state of Illinois has earned $52 million in cannabis tax revenue, with 25% going toward a community reinvestment program designed to support communities most affected by the war on drugs. And with most of the country wracked by protests against aggressive policing of these communities, these funds are much needed. “Illinois has done more to put justice and equity at the forefront of this industry than any other state in the nation, and we’re ensuring that communities that have been hurt by the war on drugs have the opportunity to participate,” says Gov. Pritzker, who pardoned more than 11,000 people with prior marijuana convictions before the program was implemented.

In May, the state announced that it would avail $31.5 million in marijuana revenue-funded restorative grants to repair the damage caused by the decades’ long war on drugs. Illinois’ legalization bill established a Restore, Reinvest, and Renew program that provides grant opportunities for “communities impacted by economic disinvestment, violence, and the severe and multilayered harm caused by the war on drugs.”

Analysts say Illinois’ success provides a shiny example that sector players like The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) can refer to when explaining the benefits of having a regulated cannabis market.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Bipedal robots have, for a long time, been struggling to walk like human beings and they have tried balancing and moving forward without falling. It has taken several years of hard work; and now the robots are starting to get comfortable with the art of walking. Their walking technique is putting them in a position of helping persons in need.

How robotic-assisted mobility works

Roboticists have launched an initiative called Robotic-Assisted Mobility Science (“RoAMS”). RoAMS is using the latest research in robotic walking in creating a new kind of medical exoskeleton. These exoskeletons can move actively using neurocontrol interfaces. The exoskeletons will also allow users to balance and walk without using the crutches necessary with existing medical exoskeletons.

However, the only way to get these exoskeletons to help people do their daily duties is through dynamic locomotion. The exoskeletons will be deployed into people’s homes to assist users in making even sandwiches and serve them. To get these bipedal exoskeletons to work with human beings is a great challenge because of the biological systems which present a lot of unknowns. A lot of research is still needed to make humans to interface with these devices successfully.

Factors such as versatility, cost, durability, and patient’s desire to use these devices with precision are other challenges that the developers are facing. However, research is still ongoing to develop an exoskeleton that can provide a good balance to people with paraplegia.

Other potential devices to help patients walk

Caltech, an exoskeleton tech firm, is also trying to develop a spinal stimulator that may help in bypassing spinal injuries. The stimulator provides an artificial connection between the muscles of the legs and the brain. RoAMS will also try borrowing this technology in exploiting the user’s muscles and nerves to assist in the control and movement of the exoskeleton even for people with total paraplegia.

Muscle and nerve coordination with motion can help people undergoing physical rehabilitation for spinal injuries or stroke. It can be very beneficial, especially when it involves walking with the exoskeleton’s assistance and support. Furthermore, it can consequently improve recovery even if the exoskeleton does most of the work.

Clinical trials and approval of the exoskeletons

Caltech is also working closely with Wandercraft, a firm in Europe, to move their research to clinical settings. An exoskeleton developed by Wandercraft has already received approval in Europe and is in use. It has already helped more than 20 paraplegics to walk.

The RoAMS initiative is planning to concentrate on directly coupling a spine interface or brain with the Wandercraft exoskeleton. The intention is to achieve a steady and active walking exoskeleton with integrated neurocontrol, which has never been developed before.

Most of these exoskeletons are designed to meet specific challenges. Cost and complexity will be the greatest challenges that make them impractical for patients with disabilities to use them since motorized wheelchairs can comfortably fulfill most of those functions. However, the RoAMS technology is trying to bring innovations to everyone in need of it, giving options where a walker or a wheelchair cannot be an option. Experts say that entities like Predictive Oncology (NASDAQ: POAI) hope that these advanced mobility products become widely available since they can be a huge help to the people lots of biomedical companies are trying to help.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Trxade Group provides a digitalized supply stream for pharmaceutical and health care services as part of its founding focus on empowering small, independent pharmacies that historically have struggled to compete against large corporate chains
• The company reported second quarter results July 27 that showed its revenues had grown 244 percent to a record $6.6 million in year-over-year quarterly results, triple the amount garnered during the first quarter of the year
• The global COVID-19 pandemic caught world markets by surprise during the spring, but Trxade’s emphasis on telemedicine and other online-accessible services positioned it as a visionary company well able to weather the health emergency
• The company has more than 50 percent penetration of its community pharmacy market nationwide and foresees further growth not only in member participation, but in fee revenue from sales-per-pharmacy metrics

The second quarter financial report of emerging pharmaceutical supplies and services provider Trxade Group (NASDAQ: MEDS) is a modern-moment testament to the hardiness of American entrepreneurial solutions under the most difficult of situations. While large segments of the population have faced easily understandable worries about the economic impacts of governmental and corporate policies responding to the potentially deadly and disabling coronavirus pandemic, many small businesses have found ways to not only survive, but to thrive.

“Revenues for the second quarter of 2020 increased 244% to a record $6.6 million, compared to revenue of $1.9 million in the same quarter last year. Sequentially, this represents an increase of 199% when compared to revenues of $2.2 million in the first quarter of 2020,” Trxade CFO Howard Doss told investors during the company’s first earnings call July 27 (http://nnw.fm/JbpUq).

Trxade’s large revenue increase was primarily due to its ability to deliver personal protective equipment at a crucial time when the pandemic was provoking a worldwide scramble to keep workers safe and businesses’ doors open to their customer bases. While the PPE-related revenue boost is unlikely to be sustainable at such a high percentage as the surprise of the pandemic’s emergence wears off, analysts have noted that Trxade’s strategy has kept it on a steady footing with a stable balance sheet, low debt and wide market penetration.

In fact, company executives have described the low-profit-margin PPE products as the reason the company’s margin dropped while revenues were increasing. CEO Suren Ajjarapu told AlphaStreet gross margin remained steady at 70 to 75 percent during the quarter in the company’s tech product sector, and that gross margins could improve once the revenue balance tips away from PPE products once the pandemic subsides (http://nnw.fm/Q9bF2).

Trxade designed its virtual platform to increase the purchasing power of small, independent pharmacies after observing the difficulties those community pharmacies faced in obtaining drug cohorts in a time-efficient and cost-effective manner. The pharmacies had “no insight or transparency into a fair market price or what others are paying for the same drug. Traditional wholesalers would provide unfavorable payment terms, (and) slow delivery,” Ajjarapu said.

The company’s B2B web-based market platform began drawing together the United States’ estimated 22,000 independent pharmacies and has now achieved more than 50 percent market penetration.

While the platform’s emphasis on transparency saves pharmacists the time-intensive tasks of having to manually compare prices across distributors and brings revenue to the company through a fee model similar to those employed by PayPal and Visa, Trxade has also expanded its own market presence through affiliated services such as those provided by its telemedicine subsidiary, a licensed online pharmacy, and a mobile application through which patients can order drugs online and get them delivered on the same day.

The affiliated services support Trxade’s push for a digitalized supply chain in the pharmaceutical space. The company’s strategies for driving growth are to increase the average purchases per pharmacy on Trxade’s platform, increasing fee revenue in the process, and to continue adding more pharmacies to the company’s network.

“I was particularly pleased with our growth in the second quarter compared to 2019, achieving record quarterly revenues, while continuing to grow average spend per pharmacy on our proprietary platform,” Ajjarapu said. “We continue to meet or exceed internal projections, while regularly attaining key milestone achievements. As a Founder of Trxade, I firmly believe that we are better positioned to create a sustainable value for our shareholders than any prior time in our history. I look forward to continued operational execution into the second half of 2020 and beyond.”

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

As 2019 drew to a close, no one expected the virus that had been discovered in Wuhan, China in November to bring the world to a complete standstill. Three months into the year, however, the resultant pandemic had caused massive damage to the economy, with industries like food service and airlines shouldering millions of job losses. Although cannabis products enjoyed a spike in sales in the week or two leading up to lockdown orders, the COVID-19 pandemic has since dampened CBD sales.

The nascent industry had previously seen extremely encouraging projections, with last year’s BDSA and Arcview Market Research industry report stating that CBD sales in the USA would surpass $20 million by 2024. However, according to a new report from Brightfield Group titled ‘US CBD Market July 2020’ CBD sales will be much lower than projected due to the coronavirus pandemic. How exactly has the pandemic affected current and future CBD sales in the country?

Stay at home orders coupled with social distancing have almost killed businesses which solely depend on their brick and mortar locations. The report by Brightfield Group noted that this would result in loss of revenue from store closures as many CBD retailers had either closed temporarily or were only offering curbside pickup or delivery.

“Even for CBD specialist retailers and smoke shops that remain open, they are experiencing steep declines in sales as social distancing guidelines and consumer worries about contracting the coronavirus keep shoppers at home,” the report says. According to Brightfield, nearly half (45%) of CBD consumers surveyed in June said they had moved their CBD purchases online, locking out up and coming players who didn’t already have infrastructure for online ordering and home delivery.

Reduced or no income due to job loss. The coronavirus pandemic has devastated the job market, with more than 20 million Americans losing their jobs since January. And as anyone who’s bought high quality CBD can attest, it isn’t cheap. And “with Americans facing high unemployment levels (11.1% in June 2020 compared to 3.8% in February 2020) year 2020 retail sales are not expected to reach levels anticipated prior to the emergence of the COVID-19 pandemic,” the report says.

As of July 14, over 30 million Americans were receiving unemployment benefits and for many of them, that’s the only income they can bank on, so CBD will probably be the last thing they want to buy. With the end of the coronavirus pandemic nowhere in sight, we can assume the economy will keep on declining, and CBD sellers who are able to adapt to the new times by incorporating online ordering, curbside pickup and home delivery will be able to weather the storm.

This less than favorable outlook for the CBD sector is likely to give industry players like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) food for thought as they plan for the coming years since the changes in consumer behavior may not go away once the pandemic ends.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

A lot of confusion and disbelief is stalling digital contact tracing efforts during the COVID-19 pandemic. A new survey shows that less than 50% of the American respondents support contact tracing apps. This indicates a lack of trust in deploying the technology and could even hinder its effectiveness.

How digital contact tracing apps work

Several contact tracing apps always try to collect some data about a smartphone user’s encounters with other people. Thereafter the app will notify the users if they are potentially coming into contact with a COVID-19 patient. However, each app works differently from the other in terms of privacy. For example, some apps collect data based on GPS, while others record close encounters with other smartphones based on Bluetooth radio-wave transmission.

Due to the difference in how the apps work, several misunderstandings have been seen in people’s opinions. The misconceptions have made it complex in assessing the public opinion of specific digital contact tracing apps. Furthermore, many more contact tracing apps are mushrooming, making the Americans hesitant to download and use them as some are not effective.

Confusion about the digital contact tracing efforts

The digital contact tracing technologies are almost similar to the traditional contact tracing, but their working is different. Traditional contact tracing is a verified-and-accurate public health measure that requires calling and interviewing large human contact tracers on a suspected or a confirmed contact with a COVID-19 patient. It also involves asking their travel history and warning family and friends who may have been exposed.

Since manual contact tracing is cumbersome and time-consuming, so most governments resort to digital contact tracing to automate the process. However, these apps work primarily by alerting the smartphone owner rather than contact tracing departments or public health officials.

The GPS based app will notify the user about their possible exposure to COVID-19 at a particular location. In contrast, the Bluetooth app will inform the user that they were exposed to someone with COVID-19 for a certain period. The difference between these two apps may make digital contact tracing more complicated and confusing.

Americans’ views about GPS-based apps and Bluetooth-based apps

From a public health viewpoint, a GPS based system is regarded as the best digital contact tracing method. However, the GPS health system may be intrusive as it may reveal the lifestyle and behavioral pattern of someone’s daily life as compared to the Bluetooth based app. From the surveys, most Americans did not view the two apps differently, whether incorporating GPS or Bluetooth. Their concerns were whether the app featured the centralized or decentralized system of data storage.

However, most of them changed their mind when it came to whether the app featured a centralized system or a decentralized system of data storage. Most people were willing to use the decentralized system as it was not sharing their personal and crucial information. For the Americans to gain trust in these apps, they need public education to correct the misinformation surrounding these apps. One wonders what suggestions entities like Genprex Inc. (NASDAQ: GNPX) have for building confidence in the technological tools being used to contain the spread of the virus.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• DarioHealth Corp. is an digital therapeutics (“DTx”) pioneer supplying remote health condition monitoring technology to caregivers and their patients
• The company recently reported a successful private placement funding transaction that provides Dario with $28.6 million in aggregate gross proceeds to build Dario’s operational strategy
• Dario’s technology allows clinical care providers to remotely observe data related to patients’ chronic conditions and also may “nudge” patients to sustain their own care
• The novel coronavirus pandemic has increased the popularity of remote patient monitoring (“RPM”) services as a means of avoiding infection risks in public healthcare settings, and legislative changes have made it easier to receive insurance reimbursement for those services

Modern technology has opened the door for a revolution in healthcare services, allowing many patients with chronic diseases to lead full and active lifestyles that may take them far from their medical providers without significant fear of repercussions thanks to communication media that support expansive health networks and, of late, telehealth and remote patient monitoring measures.

DarioHealth (NASDAQ: DRIO), a digital therapeutics innovator dedicated to providing such technology to hospitals and other medical facilities to help ensure patients receive a proper standard of care even if they are not in-clinic, recently announced a round of successful fund-raising that will help the company make its product platform more available.

The private placement transaction with accredited investors brought in approximately $28.6 million in aggregate gross proceeds (before expenses related to the offering) from healthcare funds and institutions across the United States and Israel. The company states that the new capital, combined with existing balance sheet cash, puts the company in its best financial state since its founding (http://ibn.fm/uKWvc).

“We are pleased to have the confidence of our largest shareholder and several new highly regarded healthcare investors as we expand our commercial to manage existing and anticipated near-term agreements with health care payers,” Dario CEO Erez Raphael stated. “The adoption rate of digital therapeutics has been accelerated by the current pandemic. Dario’s efficacious, value-oriented solution is well-positioned to compete in this largely untapped U.S. market.”

In this year’s report on telehealth policy, the Center for Connected Health Policy noted that telehealth policies are changing on an almost daily basis as a result of the COVID-19 novel coronavirus pandemic. CCHP’s comprehensive analysis of state Medicaid telehealth policies and laws throughout the United States was published in the spring just as COVID-19 was beginning to provoke restrictions on public events and found at the time that no two states are alike in how telehealth is treated despite some similarities in the language used.

“This variability creates a confusing environment for those who use (or intend to use) telehealth, especially health systems that provide health care services in several states,” a summary of the report states (http://ibn.fm/BsyWf).

The report notes, however, that since the report was researched and published, the pandemic has led to the creation of many temporary waivers and changes to telehealth policy across the nation. The changes include several bills passed by the U.S. federal government to support remote patient monitoring services such as those facilitated by DarioHealth’s smartphone-centered platform defined within telehealth policies (http://ibn.fm/KUQf2).

“The fear of contracting coronavirus has discouraged many people from visiting hospitals for non-Covid-19 health concerns,” Aliyah Farouk, a medical devices analyst at data analytics and consulting company GlobalData, stated in an International Travel and Health Insurance Journal interview (http://ibn.fm/eFrup). “The FDA [U.S. Food and Drug Administration] has published guidance allowing companies to expand the distribution of hospital devices for use in patients’ homes.”

Although the legislative measures encourage the Centers for Medicare and Medicaid Services to better reimburse healthcare providers for certain RPM services, in most cases the changes do not reflect a permanent shift in telehealth policy and may only be in effect through the duration of the health emergency.

Nevertheless, RPM devices that allow clinical providers to monitor patients’ conditions, ranging from apnea to diabetes and heart disease even across international boundaries, have seen a significant rise in popularity as a result of the pandemic and that may leave the door open for insurance reimbursement policy changes beyond the pandemic, which may in turn sustain further growth of RPM services.

DarioHealth is optimistic about its prospects as it pursues a long-term strategy of expanding its operational focus from the direct-to-consumer channel to a B2B2C pipeline in which working with health plans and employers grant it access to vast member, employee and patient populations. Dario believes such a model will ultimately lower customer acquisition costs and provide higher profit margins and recurring revenues.

For more information, visit the company’s website at www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Since the pandemic struck, temperature screening has been used to find those that are infected with COVID-19, and this has made your body temperature to be no longer private information. Your body temperature is soon becoming like a pass for you to access buildings. Most business premises are installing thermal imaging cameras that are fitted with facial recognition technology. They are doing so to come to terms with the COVID-19 pandemic.

Thermal scans installation in public institutions

Office buildings, government offices, fast food restaurants, airports, hospitals, and universities are quickly adopting technology. The main aim is spotting and turning away any person getting into those buildings with a fever. Theoretically, it will reduce the spread of the virus and bring some relief to individuals in the building.

Thermal cameras work by mapping body heat based on infrared radiation. The cameras focus on specific locations on the face to get the adjacent indicator of body temperature. Several firms are working towards configuring thermal cameras with facial recognition software and staff directories.

The employees will be checking in by standing in front of the camera so that the technology can identify their face and perform a thermal scan. It will take a few seconds, and no contact will be involved.

The technology is already in use in countries such as South Korea and China. PopID, a tech firm, sold several facial recognition systems that replaced fobs and key cards to access buildings. The company has since added the option of a thermal camera in its system where workers can check into work.

How PopID’s software works

The software primarily relies on proprietary algorithms in identifying both faces and finding the right facial regions for temperature scanning. According to research, the inner core of the eye is the best indicator of body temperature. The device takes the temperature measurement along the forehead and is accurate within half a degree Fahrenheit.

Furthermore, the device offers a system that frequently screens an unlimited number of people in good time about 5 meters away. The company went further to develop facial mapping, person detection, facial recognition, and other recognitions such as masks.

The Altoros Screening Device

Altoros has also developed a system that can screen large numbers of people for fever while performing face recognition. The technology is also capable of differentiating people’s faces from other warm objects. However, these thermal cameras have some shortcomings on accuracy in temperature of the environment and skin dampness.

According to the Centers for Disease Control and Prevention, these technologies are not as accurate as non-contact thermometer guns and may be difficult to use efficiently. The cameras may be ineffective as they cannot catch people with asymptomatic cases of COVID-19. However, the U.S. Food and Drug Administration has temporarily permitted marketing thermal cameras that had not been vetted.

Centers for Diseases Control and Prevention (“CDC”) verdict on thermal cameras

The CDC has raised some concerns about the technology; it says that screening for fever at airports and other premises is not an effective way to combat COVID-19. However, the companies are saying that they provide additional tools that will be used in combination with the thermal cameras to measure and help reduce COVID-19.

It remains to be seen what major players like DarioHealth Corp. (NASDAQ: DRIO) in the biomedical sector prefer to use as methods of keeping potentially infected people out of their premises.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

When the coronavirus struck in mid-March, most research work was put on hold. However, virologists had to remain active in studying different viruses similar to SARS-COV-2, a virus that causes COVID-19. It also led to the closure of schools and daycares, meaning women had to take responsibility of nurturing their children since they perform most of the work needed to raise kids.

Pandemic worsens existing inequalities

For a long time now, women have been underrepresented in scientific productivity. According to recent statistics, underrepresentation has increased by over 31%. Furthermore, these numbers have constantly reduced since the pandemic struck. Gender disparities have not only been seen in the research labs but also the submission of research articles. The number of male authors in common preprint servers increased by 6.5% while that of female-only grew by 2.6%.

The relative drop in women’s productivity started before the pandemic, but it has drastically risen after the pandemic. The decline in productivity has been attributed to factors such as childcare that have accelerated due to the closure of learning institutions. Furthermore, being a single mother is also another factor that has stalled their productivity.

Besides, the division of labor at homes has not been equal. Surveys indicated that women were doing more of the house duties as compared to what their male counterparts were doing. Furthermore, women also took care of old and sick relatives, hence reducing their scientific research contribution. Female academics have also been doing a lot of teaching than male scholars, and the transition to online education has also affected their research productivity.

Gender disparities may bring some consequences for COVID-19 research

The gender gap is going to affect COVID-19 research. Several surveys have indicated that only one-third of women authors have participated in the coronavirus research. Besides, women may be relegated from senior author positions to less influential lower authorship posts. Similarly, female economists have also experienced a drop in productivity during the pandemic. Analysis has indicated that female economists are less likely to publish on COVID-19 related issues than their male counterparts.

It is, therefore, beneficial to include more women researchers, especially with the COVID-19 pandemic, as it affects men and women differently. Women should thus be engaged in shaping the research response to this pandemic. Other groups such as the Hispanics, Native Americans, and blacks who are underrepresented in the scientific research should also be included as they have been unequally affected by the pandemic.

Having all these groups in designing drugs, vaccine trials, and other COVID-19 researches will ensure a better and complete result. It could give more room to publish the findings and could also attract more funding. Therefore, it is necessary to provide equal opportunities to both genders to avoid gender disparities, especially during the pandemic. Experts say companies like Predictive Oncology (NASDAQ: POAI) may already be implementing in-house solutions to the problems that their female staff are facing during this time.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Synthetic biology is becoming an important tool in a wide range of applications. In the sector of drug discovery, there are many areas where synthetic biology has played a vital role in faster and accurate drug development at lower expenses. With an increased application of DNA sequencing, synthetic biology is becoming essential to biotech and pharma scientists.

Furthermore, the tool has empowered drug discovery scientists to clone and synthesize DNA fragments to develop new drugs. Through it, researchers have resorted to automated platforms for rapid DNA synthesis. This technology is being looked at to generate more vaccine candidates for the SARS-COV-2 Virus faster than the more usual way.

Application of Synthetic Biology

Synthetic biology mechanisms have gained pace in the drug discovery channel. The tool is helping scientists in several areas in preclinical and clinical research. A major use of synthetic biology is developing a cell-free system that allows scientists to analyze and activate biology machinery. It is done without the baffling number of variables introduced by a live cell system. Furthermore, advanced synthetic systems have brought new ways of manipulating body systems for a better understanding of biology and the discovery of new drugs.

Rapid and accurate synthesis of DNA has been of benefit to the drug discovery process. The process has been very important, especially where cost and time-sensitive needs had to be considered in generating DNA fragments and expression of vectors or variant libraries. The advancement in synthetic biology techniques can be used to boost natural polymerases that can produce dozens of DNA fragments overnight.

Besides, synthesized clones and variant libraries can be essential in discovery biology, epitope grading, protein, and antibody engineering. Recently, variant libraries produced by synthetic biology were used by some researchers in designing and assembling a series of nanobody sequences. By using synthetic biology, the outcome was three times faster than using manual benchtop cloning methods. Additionally, synthetic biology has also been paired with CRISPR methods to aid in gene therapy development and disease modeling.

Speedy Vaccine Development

The broad gains of synthetic biology in drug discovery can be demonstrated in the recent efforts to develop vaccines for COVID-19. Besides, the tool was also successfully used to develop vaccines for the H7N9 avian flu, which never turned into a pandemic. Modern automation has also been availed in time for the emergence of the SARS-COV-2 outbreak.

Scientists have also been able to take genome assemblies produced by SARS-COV-2 and have used the sequence to come up with genomic constructs for potential vaccines, and so far five potential vaccines have been identified. The timeframe for testing these vaccines has also been reduced, courtesy of synthetic biology.

With this type of speed via synthetic biology, researchers are even aiming to develop region-specific vaccines. Such localized vaccines will be more effective and will even respond to localized mutations. The approach can also be viable for vaccines using the RNA, live attenuated virus, DNA, or viral vectors.

Seeing ahead

New approaches in synthetic biology have made this technology more accurate, more affordable, and faster. These advances are bringing synthetic biology to the field of drug discovery, which was not achievable before. Scientists have already demonstrated that implementing an automated synthetic biology podium can accelerate discovery research and speed the development of new therapies, so we should expect a lot in this direction from firms like Genprex Inc. (NASDAQ: GNPX).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The presence of SARS-COV-2 in cats and dogs has caught the attention of scientists. Many scientists have been researching whether the pets can transmit other pathogens, such as drug-resistant bacteria, to human beings.

Effects of multidrug-resistant organisms crossing from pets to humans

A puppy had exhibited some signs of the coronavirus in North Carolina after three people from the family that owned it had tested positive for the disease. There were concerns about whether the pup had contracted the disease or not. However, after testing samples, the results were negative, but other pets in the same household had tested positive for the virus. It was a great concern for the scientists to see if the pets could transmit the virus to one another or to human beings.

It is not only COVID-19 that scientists are worried about, but they have also been studying whether multidrug-resistant organisms are transferrable from pets to humans. Cases of humans being infected by pet food have been recorded in many instances. For instance, more than 150 people in different states were infected with a multidrug resistant salmonella. It occurred after they had handled a contaminated pig-ear pet treat. Pet food has also been a source of antibiotic-resistant bacteria, according to multiple pieces of research.

Some researchers have therefore resorted to testing raw dog food to establish whether it hosts some of these multidrug-resistant bacteria. The researchers realized that the dog food harbored the antibiotic-resistant Enterococcus faecium, and this bacteria has been responsible for causing a lot of infections worldwide. The diseases are due to humans sharing some antibiotic-resistant species of Enterococcus with dogs. However, the origin of transmission has not been found yet.

Are pets capable of infecting humans with multidrug-resistant bacteria?

Two researchers gathered samples of dog foods from various outlets to ascertain if these contained multidrug-resistant bacteria. Samples of 15 dry foods, 22 wets, and 9 raw frozen food were collected. The three types of food were swabbed in agar plates to culture any living bacteria in it. The plates were then treated with antibiotics, and all the samples in the frozen raw food tested positive for multidrug resistant enterococci.

Only one sample of wet food and none of the dry foods had traces of resistant antibiotics. However, it was expected that the amount of those bacteria in the raw foods would be more than those in dry foods since they are not sterilized. The research also showed that some of the raw foods’ bacterial strains had mobile elements that promote antibiotic resistance. Some of those resistant strains had also been identified in people with a bacterial infection.

However, from the analysis, the overall evidence is weak that a large number of antibiotic-resistant bacteria are transferred from pets to humans at levels that can make humans sick. In case the transmission from pets to humans happens, then instances of infections are very rare.

It would be interesting to know what progress biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) are making in finding lasting solutions to some of these superbugs threatening human health.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.